MEDINET
Home Site Map Japanese
Corporate Information About Immuno-Cell Therapy Research and Development Press Release IR Information Inquiaries
Home　≫　About Immuno-Cell Therapy　≫　Immuno-Cell Therapy Total Support Service　≫　Technology Pipelines
　
Immuno-Cell Therapy General Support Service
About Immuno-Cell Therapy
　 Immuno-Cell Therapies
Business Model
　 Technology Pipelines
　 Further Service Development
Safety and Quality Control
ISO 9001 Qualified Service
Introduction of Cell
Processing Center
[Video] Immuno-Cell: Cytotoxicity towards Cancer Cell
　

We offer Immuno-Cell Therapy Total Support Service to medical institutions in order to support their medical practice for conducting immuno-cell therapy in safe and efficient manner. Our technology pipelines of immuno-cell therapy are described as below;-
1. Dendritic Cell Vaccine Therapy
2. αβT-cell Therapy (Alpha-Beta T-cell Therapy)
3. γδT-cell Therapy (Gamma-Delta T-Cell Therapy)
4. CTL Therapy (Cytotoxic T-Lymphocyte Therapy)
 
1. Dendritic Cell Vaccine Therapy

Monocytes are isolated from peripheral blood of patient, and are differentiated to DCs. Such DCs are cultured with proteins extracted from cancer cells or synthesized peptides (conjunctions of several to somedozen of amino acids,) which enable DCs to present antigens on their surface. Then DCs are reinfused to the patient. It is expected that those antigen-presenting cells induce tumor-specific T lymphocytes by and presenting them to T-lymphocytes in-vivo.

We originally developed DC Vaccine therapy using DCs co-pulsed with tumor antigen and Zoledronate. We also brought the electroporation technology, Cell Loading System, into the DCs cell processing. By the combination of those technologies, DCs can efficiently take up more tumor antigens, resulted in higher induction of tumor antigen-specific CTLs.
2. αβT-cell Therapy (Alpha-Beta T-cell Therapy)
Lymphocytes, including αβT-cell, γδT-cell, NK cell, and other cells, are isolated from peripheral blood of a patient. Such lymphocytes are activated and proliferated with anti-CD3 antibodies and interleukin-2 outside of his/her body, and then are reinfused to the patient.
After the activation of the lymphocytes, number of the αβT-cells will be approximately 90% of all of the cells.


3. γδT-cell Therapy (Gamma-Delta T-Cell Therapy)
Lymphocytes, including αβT-cell, γδT-cell, NK cell, and other cells, are isolated from peripheral blood of a patient. Such lymphocytes are selectively activated and proliferated with mixture of aminobisphosphonate, Zoledronate, and interleukin-2 outside of his/her body, and then are reinfused to the patient.
After the activation of the lymphocytes, number of the γδT-cells will be much more than the αβT-Cell Therapy.
4. CTL Therapy (Cytotoxic T-Lymphocyte Therapy)
T-Lymphocytes are isolated from peripheral blood of a patient. Such lymphocytes are activated and induced as Cytotoxic T-Lymphocytes (“CTL”) specific to cancer cells by using tumor antigens derived from pleural or peritoneal effusion of the cancer patient, and then are reinfused to the patient.

In addition, we carry out several R&D activities for development of novel advanced technologies in immuno-cell therapy, as we continue to aim for bringing better technologies into the public. Therefore, we support medical institutions by licensing or providing such novel technologies of immuno-cell therapy as the Immuno-Cell Therapy Total Support Service.

　
　 　 　 　
　 　 　
Return to Top
　
MEDINET Co., Ltd.